Wetenschappelijke publicaties van Bordet

Wetenschappelijke publicaties van Bordet

PD-L1 Expression in Paired Samples of Rectal Cancer.

Coussement M, Fazio R, Audisio A, El Khoury R, Abbassi FZ, Assaf I, Conti C, Gallio C, Benhima N, Bregni G, Gkolfakis P, Spagnolo V, Anthoine G, Liberale G, Moretti L, Martinive P, Hendlisz A, Demetter P, Sclafani F

PD-L1 Expression in Paired Samples of Rectal Cancer.

PD-L1 Expression in Paired Samples of Rectal Cancer.

Coussement M, Fazio R, Audisio A, El Khoury R, Abbassi FZ, Assaf I, Conti C, Gallio C, Benhima N, Bregni G, Gkolfakis P, Spagnolo V, Anthoine G, Liberale G, Moretti L, Martinive P, Hendlisz A, Demetter P, Sclafani F

PD-L1 Expression in Paired Samples of Rectal Cancer.

PD-L1 Expression in Paired Samples of Rectal Cancer.

Coussement M, Fazio R, Audisio A, El Khoury R, Abbassi FZ, Assaf I, Conti C, Gallio C, Benhima N, Bregni G, Gkolfakis P, Spagnolo V, Anthoine G, Liberale G, Moretti L, Martinive P, Hendlisz A, Demetter P, Sclafani F

PD-L1 Expression in Paired Samples of Rectal Cancer.

PD-L1 Expression in Paired Samples of Rectal Cancer.

Coussement M, Fazio R, Audisio A, El Khoury R, Abbassi FZ, Assaf I, Conti C, Gallio C, Benhima N, Bregni G, Gkolfakis P, Spagnolo V, Anthoine G, Liberale G, Moretti L, Martinive P, Hendlisz A, Demetter P, Sclafani F

PD-L1 Expression in Paired Samples of Rectal Cancer.

Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions.

Mjaess G, Haddad L, Jabbour T, Baudewyns A, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Oderda M, Gontero P, Bernal-Gomez A, Mastrorosa A, Roche JB, Abou Zahr R, Ploussard G, Fiard G, Halinski A, Rysankova K, Dariane C, Delavar G, Anract J, Barry Delongchamps N, Bui AP, Taha F, Windisch O, Benamran D, Assenmacher G, Benijts J, Guenzel K, Roumeguère T, Peltier A, Diamand R

Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions.

Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions.

Mjaess G, Haddad L, Jabbour T, Baudewyns A, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Oderda M, Gontero P, Bernal-Gomez A, Mastrorosa A, Roche JB, Abou Zahr R, Ploussard G, Fiard G, Halinski A, Rysankova K, Dariane C, Delavar G, Anract J, Barry Delongchamps N, Bui AP, Taha F, Windisch O, Benamran D, Assenmacher G, Benijts J, Guenzel K, Roumeguère T, Peltier A, Diamand R

Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions.

Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions.

Mjaess G, Haddad L, Jabbour T, Baudewyns A, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Oderda M, Gontero P, Bernal-Gomez A, Mastrorosa A, Roche JB, Abou Zahr R, Ploussard G, Fiard G, Halinski A, Rysankova K, Dariane C, Delavar G, Anract J, Barry Delongchamps N, Bui AP, Taha F, Windisch O, Benamran D, Assenmacher G, Benijts J, Guenzel K, Roumeguère T, Peltier A, Diamand R

Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions.

Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions.

Mjaess G, Haddad L, Jabbour T, Baudewyns A, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Oderda M, Gontero P, Bernal-Gomez A, Mastrorosa A, Roche JB, Abou Zahr R, Ploussard G, Fiard G, Halinski A, Rysankova K, Dariane C, Delavar G, Anract J, Barry Delongchamps N, Bui AP, Taha F, Windisch O, Benamran D, Assenmacher G, Benijts J, Guenzel K, Roumeguère T, Peltier A, Diamand R

Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions.

Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions.

Mjaess G, Haddad L, Jabbour T, Baudewyns A, Bourgeno HA, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Oderda M, Gontero P, Bernal-Gomez A, Mastrorosa A, Roche JB, Abou Zahr R, Ploussard G, Fiard G, Halinski A, Rysankova K, Dariane C, Delavar G, Anract J, Barry Delongchamps N, Bui AP, Taha F, Windisch O, Benamran D, Assenmacher G, Benijts J, Guenzel K, Roumeguère T, Peltier A, Diamand R

Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions.
Erasme hospital

Erasmusziekenhuis

Bekijk alle wetenschappelijke publicaties van Erasmus

Wetenschappelijke publicaties van Erasmus
Huderf hospital

Queen Fabiola Kinderziekenhuis

Bekijk alle wetenschappelijke publicaties van het Koningin Fabiola Kinderziekenhuis

Wetenschappelijke publicaties van het Koningin Fabiola-Kinderziekenhuis
Bordet hospital

Jules Bordet-instituut

Bekijk alle wetenschappelijke publicaties van Jules Bordet

Wetenschappelijke publicaties van Jules Bordet